This publication describes 3 cases where patients with chronic and recurrent S. aureus-related dermatoses were successfully treated with Staphefekt SA.100, the active ingredient of Gladskin. The results indicate that targeted treatment with Staphefekt might be an attractive alternative for (long-term) classical antibiotic therapy.
Successful Treatment of Chronic Staphylococcus aureus-Related Dermatoses with theTopical Endolysin Staphefekt SA.100: A Report of 3 Cases
Share this article
Find out more
Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis